← 返回

用于结直肠癌免疫治疗的 CAR-T 细胞:准备就绪了吗?

英文原题:CAR T-cells for colorectal cancer immunotherapy: Ready to go?

查看英文原题

CAR T-cells for colorectal cancer immunotherapy: Ready to go?

PubMed 2022/11/15(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)T细胞代表了一种新的基因工程化细胞免疫治疗工具,用于对抗癌症。CAR-T 细胞的应用已经彻底改变了血液系统恶性肿瘤的治疗方法。遗憾的是,要将这种治疗开发用于实体瘤(包括结直肠癌),还有很长的路要走。CAR-T 细胞治疗结直肠癌仍处于早期阶段,临床数据稀缺。该疗法的主要局限性包括高毒性、复发以及结直肠癌中CAR-T 细胞治疗难以渗透的肿瘤微环境。在这篇综述中,我们总结了当前的知识,强调了挑战,并讨论了CAR-T 细胞治疗结直肠癌的前景。

展开英文摘要原文

Chimeric antigen receptor (CAR) T-cells represent a new genetically engineered cell-based immunotherapy tool against cancer. The use of CAR T-cells has revolutionized the therapeutic approach for hematological malignancies. Unfortunately, there is a long way to go before this treatment can be developed for solid tumors, including colorectal cancer.

CAR T-cell therapy for colorectal cancer is still in its early stages, and clinical data are scarce. Major limitations of this therapy include high toxicity, relapses, and an impermeable tumor microenvironment for CAR T-cell therapy in colorectal cancer. In this review, we summarize current knowledge, highlight challenges, and discuss perspectives regarding CAR T-cell therapy in colorectal cancer.

论文信息

作者
Ghazi B、El Ghanmi A、Kandoussi S、Ghouzlani A、Badou A
第一作者单位
Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.
通讯作者单位
Immuno-Genetics and Human Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 36458008 · DOI 10.3389/fimmu.2022.978195